Catalog 01 Resources 02 How to order 03 CalculatorBlog Cart 03 Home 04
GH & Secretagogues

CJC-1295 + Ipamorelin 10mg Australia — Co-Lyophilised

CJC-1295 without DAC 10mg + IPA 10mg research peptide vial — TXLABS, ≥98% HPLC

From $129 AUD · ≥98% HPLC purity · third-party COA · ships Australia-wide

What is CJC-1295 without DAC 10mg + IPA 10mg?

CJC-1295 without DAC + Ipamorelin (IPA) is a research blend pairing a short-acting GHRH analogue with a selective ghrelin receptor agonist. This 10mg + 10mg combination is studied for complementary growth hormone release, as Mod GRF 1-29 acts on the GHRH receptor and Ipamorelin on the ghrelin/GHS-R pathway.

Specifications

What the research covers

This vial contains two distinct research peptides co-lyophilised into a single cake, nominally 10 mg of CJC-1295 without DAC and 10 mg of ipamorelin, 20 mg of peptide in total. It is the double-strength form of the 5 mg plus 5 mg blend also stocked here. The two are separate molecules acting at separate receptors and a certificate should treat them separately.

CJC-1295 without DAC is more precisely described as modified GRF(1-29), a truncated analogue of growth hormone-releasing hormone. It uses the first 29 residues of GHRH, the shortest fragment reported to retain full agonist activity, with four amino acid substitutions reported as D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27. The D-Ala substitution is the functionally important one, blocking dipeptidyl peptidase-4 cleavage at the N-terminus, which is the principal degradation route for native GHRH. Its molecular weight is in the region of 3.4 kDa. The without DAC designation denotes the absence of the drug affinity complex, the maleimide group that allows the DAC-modified version to bind covalently to serum albumin.

Ipamorelin is a pentapeptide of 711.9 Da acting at the growth hormone secretagogue receptor GHS-R1a, the ghrelin receptor. It is a synthetic molecule with no sequence relationship to GHRH or to ghrelin. Research literature pairs GHRH analogues with GHS-R1a agonists because they represent two independent inputs converging on the same pituitary somatotroph population, and published work in cell and animal models has examined whether combined receptor engagement produces additive or synergistic secretory responses.

TXLABS supplies this blend as an analytical reference material for laboratory research only. It is not an approved therapeutic good in Australia and is not supplied for human or veterinary administration.

Reading the certificate

Per-component assay is the whole question for a blend, and here the components are easy to separate, so there is no technical excuse for a combined figure. At roughly 3.4 kDa and 711.9 Da the two masses are far apart and unambiguous by mass spectrometry, and their reversed-phase retention differs markedly. Ask for two purity figures, two observed masses and two content values, and confirm the ratio matches the label rather than assuming it. For the GHRH analogue specifically, ask whether the method resolves the methionine sulfoxide, and whether the substitution pattern was confirmed, since modified GRF(1-29) differs from plain sermorelin at four positions and the two are close in mass. Salt form and net peptide content should be stated for each. TXLABS publishes third-party certificates for tested lots in the CoA library; no certificate is currently published for this blend. The lot certificate is available on request to support@txlabs.bio.

Storage and handling

A blend is stored on the terms of its least stable component, and here that is the 29-residue GHRH analogue rather than the pentapeptide. Modified GRF(1-29) carries several liabilities at once: methionine, which oxidises to the sulfoxide with a sixteen dalton shift, asparagine and aspartate residues subject to deamidation and isomerisation, and a tendency to aggregate at high concentration. Ipamorelin at five residues is chemically far more robust, containing no cysteine and no methionine, and it is not the component that sets the storage terms.

The consequence for a blend is that differential degradation shifts the ratio with no visible sign. A vial can look correct, assay correctly for total peptide, and contain a different ratio than the label states.

Store the cake at -20 C, desiccated and protected from light, and equilibrate the sealed vial before opening so moisture does not condense onto a hygroscopic powder. Once reconstituted the two peptides share one solution and every decision applies to both: hold at 2-8 C in the dark, add diluent gently down the vial wall, swirl rather than shake, and aliquot before freezing. Australian summer transit above 40 C produces exactly that silent shift.

Working out concentration

For a blend, concentration has to be tracked per component or the record is meaningless. This vial holds nominally 10 mg of CJC-1295 without DAC and 10 mg of ipamorelin, 20 mg of peptide in total. Reconstituted with 2 mL of bacteriostatic water it gives 5 mg/mL of each and 10 mg/mL of total peptide; with 4 mL, 2.5 mg/mL of each and 5 mg/mL total; with 1 mL, 10 mg/mL of each and 20 mg/mL total. Recording only the total is the common error, since it doubles the apparent concentration of either component. Note also that the 5 mg plus 5 mg blend at the same diluent volume gives exactly half these figures. The reconstitution calculator handles the arithmetic. Concentration examples only, not a protocol.

How it relates to adjacent compounds

Both components are stocked individually as CJC-1295 without DAC and ipamorelin, and those pages carry the detail on each molecule. The same pairing is stocked at half strength as CJC-1295 without DAC 5 mg with ipamorelin 5 mg, which is chemically identical and differs only in mass. CJC-1295 with DAC is the albumin-binding variant and is a materially different molecule, not an alternative presentation of the same one. The tesamorelin and ipamorelin blend listed separately pairs a different GHRH analogue with the same secretagogue at an unequal ratio, so it is a different product rather than a variant of this one. These are structural and design adjacencies only, and imply nothing about comparable activity.

Frequently asked questions

How does this differ from the 5 mg plus 5 mg blend? +
Only in mass. The molecules are identical and the ratio is the same; this vial holds twice as much of each component, 20 mg of peptide in total against 10 mg. The practical consequence is arithmetic: at any given diluent volume this vial produces exactly double the per-component concentration of the smaller blend, which is worth confirming rather than assuming.
Why are these two peptides paired? +
Because they act at separate receptors that converge on the same pituitary somatotroph population. Modified GRF(1-29) acts at the GHRH receptor and ipamorelin at the growth hormone secretagogue receptor GHS-R1a. Published work in cell and animal models has examined whether engaging both produces additive or synergistic secretory responses. The pairing reflects that research question, not a formulation finding.
What does without DAC actually mean? +
It denotes the absence of the drug affinity complex, a maleimide group that allows the DAC-modified version of CJC-1295 to bind covalently to serum albumin. That modification is what gives the DAC version a very different reported circulating persistence. The two versions are therefore different molecules with different masses, not two presentations of the same compound.
Which component sets the storage conditions? +
The GHRH analogue. At 29 residues it contains methionine, which oxidises readily, and asparagine and aspartate residues subject to deamidation and isomerisation, and it is prone to aggregation at high concentration. Ipamorelin at five residues has none of those liabilities. Conditions that leave the pentapeptide untouched can degrade the longer peptide and shift the ratio invisibly.
How would the GHRH analogue be confused with sermorelin? +
Sermorelin is unmodified GHRH(1-29). Modified GRF(1-29) is the same 29-residue framework with four substitutions, so the two are close in mass and similar in chromatographic behaviour. A certificate that names the analyte loosely, or reports a mass without confirming the substitution pattern, leaves open which of the two is actually present, and they are not interchangeable.
Can the two peptides be separated after reconstitution? +
Not practically outside an analytical laboratory. Once diluent is added they share a single solution. That is why per-component figures on a certificate matter: they are the only record of how much of each molecule the vial held before reconstitution, and the reason concentration should be tracked per component rather than as a single total.

Related compounds

Browse full catalog Reconstitution calculator